Significant milestone for Poolbeg's IP portfolio

AI SummaryClose X

Poolbeg Pharma PLC has announced a significant milestone with the grant of its first patent for cancer immunotherapy-induced Cytokine Release Syndrome (CRS) by IP Australia, covering the use of p38 MAPK inhibitors, including POLB 001, for prevention. This patent strengthens the company's global intellectual property portfolio and enhances the future value and partnership appeal of POLB 001, with interim data from the TOPICAL trial expected in summer 2026. The company is actively pursuing patent coverage in other jurisdictions, leveraging the Patent Prosecution Highway for expedited review.

Disclaimer*

UK 100

Latest directors dealings